2023-10-10 09:36:15 ET
DENVER, Colo., Oct 9, 2023 ( www.247marketnews.com )- Immunic, Inc. (NASDAQ: IMUX) reported, after yesterday’s market close, positive interim data from its phase 2 CALLIPER trial of nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with progressive multiple sclerosis (PMS). The 24-week data from the first half of patients shows improvements in biomarker NfL, consistent throughout the overall progressive multiple sclerosis population, as well as all subtypes, which Immunic believes shows biomarker evidence that vidofludimus calcium’s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective potential.
Immunic is trading at $1.87, up $0.28 (+17.61%), up 5.81M premarket shares traded.
Its 52-week range is $1.11 to $11.76. Its next inflection points are $1.90 and …
The post Immunic Reports Positive Phase 2 CALLIPER Trial Interim Data appeared first on 24/7 Market News .
For further details see:
Immunic Reports Positive Phase 2 CALLIPER Trial Interim Data